GR3003631T3 - - Google Patents

Info

Publication number
GR3003631T3
GR3003631T3 GR910401306T GR910401306T GR3003631T3 GR 3003631 T3 GR3003631 T3 GR 3003631T3 GR 910401306 T GR910401306 T GR 910401306T GR 910401306 T GR910401306 T GR 910401306T GR 3003631 T3 GR3003631 T3 GR 3003631T3
Authority
GR
Greece
Prior art keywords
nifedipine
concentrate
vitamin
surfactant
appropriate
Prior art date
Application number
GR910401306T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3003631T3 publication Critical patent/GR3003631T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GR910401306T 1986-12-18 1992-01-23 GR3003631T3 (2)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP86117660A EP0272336B1 (de) 1986-12-18 1986-12-18 Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
GR3003631T3 true GR3003631T3 (2) 1993-03-16

Family

ID=8195654

Family Applications (1)

Application Number Title Priority Date Filing Date
GR910401306T GR3003631T3 (2) 1986-12-18 1992-01-23

Country Status (7)

Country Link
US (1) US4904699A (2)
EP (1) EP0272336B1 (2)
JP (1) JPS63165318A (2)
AT (1) ATE68704T1 (2)
DE (1) DE3682208D1 (2)
ES (1) ES2040697T3 (2)
GR (1) GR3003631T3 (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
HUT59592A (en) * 1990-07-20 1992-06-29 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of solid medical products
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
IN186245B (2) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
ES2304980T3 (es) * 1999-09-30 2008-11-01 Penwest Pharmaceuticals Co. Sistemas de matriz de liberacion sostenida para farmacos altamente solubles.
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1511470A2 (en) * 2003-03-26 2005-03-09 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
GB0703514D0 (en) * 2007-02-23 2007-04-04 Univ Ulster Use of riboflavin
HK1198296A1 (en) * 2012-02-16 2015-03-27 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
CA2968861C (en) 2017-05-30 2022-10-11 University Of Saskatchewan Topical nifedipine formulations and uses thereof
JP7443663B2 (ja) * 2018-11-07 2024-03-06 ディーエスエム アイピー アセッツ ビー.ブイ. 改善された流動性を示す、リボフラビンを含有する薬剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (2) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
GB2111978B (en) * 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3532129A1 (de) * 1985-09-10 1987-03-12 Bayer Ag Ss-carotin enthaltende gelatine

Also Published As

Publication number Publication date
JPS63165318A (ja) 1988-07-08
ATE68704T1 (de) 1991-11-15
EP0272336B1 (de) 1991-10-23
ES2040697T3 (es) 1993-11-01
DE3682208D1 (de) 1991-11-28
US4904699A (en) 1990-02-27
EP0272336A1 (de) 1988-06-29

Similar Documents

Publication Publication Date Title
GR3003631T3 (2)
GR3000536T3 (en) Penetration enhancement systems and the preparation thereof
AU3438284A (en) Sucralfat-suspension
DK554084A (da) 26,26,26,27,27,27-hexafluor-1alfa,25-dihydroxycholesterol
IT8523299A0 (it) Derivati. processo per la preparazione di (2,2)-paraciclofano e suoi
DE3782182D1 (de) Azacycloalkanderivate, absorptionspromotoren, die die derivate als effektiven inhaltsstoff enthalten und aeusserlich anzuwendende praeparate, die absorptionspromotoren enthalten.
EP0276543A3 (en) Use of buspirone for the improvement of short term memory
DZ629A1 (fr) Dérivés de la furo-(3,4-c)-pyridine ainsi que leurpréparation.
EP0227450A3 (en) Substituted 5,6-dialkoxyquinazoline derivatives
DZ768A1 (fr) Dérivés de l'hydroxy-4-2h-1-benzothiopyran-2-one, leurs préparations et applications.
AU6284386A (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-111/lav by 2' 3' -dideoxycytidine
EP0331092A3 (en) Alpha-amino-carboxylic-acid derivatives, their preparation and use
FI854425A0 (fi) Anordning foer uppvaermning av passagerarutrymmen eller liknande, speciellt i bussar.
EP0204586A3 (en) Stabilizer for hair compositions and such compositions
DK0437225T3 (da) Topiske præparater
IT8420213A0 (it) Procedimento per la preparazione di 1,8-diidrossi-10-acil-9-antroni, in particolare per l'uso nel trattamento di psoriasi.
DE3484355D1 (de) Gefaerbte wasserfreie mittel fuer kosmetische, medizinische und aehnliche zwecke, sowie deren herstellung.
NO860273L (no) Fremgangsmaate for fremstilling av 4,4-dialkyl-2-azetidinoner.
Ghosh Geochemistry of the Nelson-Rossland Area, Southeastern British Columbia
EP0098568A3 (en) Corticoids-containing preparation for topical application
TR23253A (tr) Zorunlu olarak sodyum suelfat meydana gelmeden parafin-sulfoksidasyon-reaksiyon karisimlarindan alkali suelfat bakimindan fakir parafin suelfonot'larinin ve suelfuerik asidin izde edilmesine mahsus usul
NO863094D0 (no) Fremgangsmaate for fremstilling av 5-klor-s-triazolo-(4,3-a)-pyridin-7-carboxylsyrer.
小田光宏 White, MD “Evaluation of the reference interview”
Pedras Metabolites of the Scleroderris canker fungus
ZA874878B (en) Pyran derivatives